Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to develop a better tolerated and more effective pharmacologic
treatment with individuals with Pervasive Developmental Disorder. This is a double-blind,
placebo-controlled study of aripiprazole in the management of the maladaptive behaviors of
Pervasive Developmental Disorder. The investigators hypothesize that aripiprazole will be
more effective than placebo for reducing aggression, tantrum and self-injurious behavior in
children with Pervasive Developmental Disorder.
Phase:
Phase 3
Details
Lead Sponsor:
Indiana University
Collaborators:
Bristol-Myers Squibb National Institute of Mental Health (NIMH)